Selank vs ARA-290
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Selanc, TP-7
Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built from the natural immune peptide tuftsin, with a small chemical tweak to make it last longer in the body. It was developed in Russia as an anti-anxiety and nootropic agent and is approved there for generalized anxiety disorder, but it has no FDA or EMA approval and almost no Western clinical data. The pitch is calm and focus without the sedation, dependence, or withdrawal that come with benzodiazepines.
Also: Cibinetide, ARA 290
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (EPO), engineered to calm inflammation and repair nerves without thickening the blood the way EPO does. It has been tested in real Phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds FDA orphan drug status, but it was never approved and development largely stalled. So: genuine clinical data, promising signals, no finish line.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Selank | ARA-290 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Selank seems to work through several overlapping systems rather than one tidy target. It influences GABA signaling, the brain's main calming neurotransmitter system, which likely accounts for its anti-anxiety effect. It also slows the breakdown of enkephalins, the body's own opioid-like peptides involved in mood and stress, which is a mechanism entirely different from benzodiazepines or SSRIs. Animal work additionally points to effects on serotonin and dopamine balance and on BDNF, a growth factor tied to learning and neuron health. These pathways are well documented in rodents; the picture in humans is inferred rather than directly measured. | EPO does two jobs - it tells bone marrow to make red blood cells, and separately it protects and repairs injured tissue. ARA-290 was designed to trigger only the second job. It selectively activates the innate repair receptor (IRR), a heteroreceptor that pairs the EPO receptor with the CD131 beta-common chain and shows up at sites of injury and inflammation. By switching on this receptor, the peptide dampens inflammatory signaling and reduces cell death while leaving red blood cell production alone, which sidesteps EPO's clotting and cardiovascular risks. Some research also links its pain-relieving effect to modulation of the TRPV1 channel where the immune system and nociception intersect. |
| Common Dosing | 250-500 mcg intranasal 2-3x daily 2-3x daily, intranasal | 4 mg daily Once daily |
| Administration | Intranasal spray (most common), subcutaneous injection | Subcutaneous injection |
| Typical Duration | 14-21 days typical | 28-day courses in trials |
| Best Time to Take | Morning or as needed for anxiety | Consistent daily timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Most of the rigorous data is preclinical and Russian. In rodents, Selank shows consistent anxiety-reducing and mild cognitive effects, and one PMC-indexed study found it enhanced diazepam's anti-anxiety effect under chronic stress. The main human clinical reference is a Russian comparative trial by Zozulia, Neznamov, and colleagues in patients with generalized anxiety disorder and neurasthenia, reporting that Selank's anxiolytic effect was comparable to the benzodiazepine medazepam on standard rating scales, with added anti-fatigue benefits and changes in enkephalin activity. The honest caveat: that trial was relatively small, the published English abstract gives qualitative results rather than hard effect sizes and p-values, and it has not been replicated by independent Western groups. So the evidence supports a real but modestly studied anxiolytic, mostly validated within the regulatory system that approved it. | ARA-290 has more real human data than most peptides in this category. A 2015 phase 2 trial published in Molecular Medicine (Brines et al., registered as NTR3858) found that ARA-290 improved hemoglobin A1c and lipid profile and significantly improved PainDetect neuropathic symptom scores in type 2 diabetes patients, with increased corneal nerve fiber density in those with small fiber neuropathy. In sarcoidosis-associated small fiber neuropathy, controlled studies reported increased corneal nerve fiber area and more regenerating (GAP-43-positive) skin nerve fibers, though in at least one dose-ranging trial pain did not clearly separate from placebo - an honest caveat worth keeping. Tolerability in these small, early-phase studies has been favorable, with no signal of EPO-style blood thickening. That said, the trials are small and early, ARA-290 holds FDA orphan drug status for sarcoidosis neuropathy but is not approved, and the program stalled around 2020. Net: real clinical evidence pointing in a hopeful direction, but not yet proven enough to be a standard treatment. |
Frequently Asked Questions: Selank vs ARA-290
What is the difference between Selank and ARA-290?
Selank is a cognitive peptide that selank is a synthetic seven-amino-acid peptide (thr-lys-pro-arg-pro-gly-pro) built from the natural immune peptide tuftsin, with a small chemical tweak to make it last longer in the body. it was developed in russia as an anti-anxiety and nootropic agent and is approved there for generalized anxiety disorder, but it has no fda or ema approval and almost no western clinical data. the pitch is calm and focus without the sedation, dependence, or withdrawal that come with benzodiazepines. ARA-290 is a cognitive peptide that ara-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (epo), engineered to calm inflammation and repair nerves without thickening the blood the way epo does. it has been tested in real phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds fda orphan drug status, but it was never approved and development largely stalled. so: genuine clinical data, promising signals, no finish line. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Selank or ARA-290?
Neither is universally "better" - the choice depends on your specific goals. Selank is typically used for cognitive purposes, while ARA-290 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Selank and ARA-290 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Selank and ARA-290 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.